Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma. 2011

Denis Faoro, and André O von Bueren, and Tarek Shalaby, and Davide Sciuscio, and Marie-Louise Hürlimann, and Lucia Arnold, and Nicolas U Gerber, and Johannes Haybaeck, and Michel Mittelbronn, and Stefan Rutkowski, and Monika Hegi, and Michael A Grotzer
Neuro-Oncology Program, University Children's Hospital, Steinwiesstrasse 75, 8032 Zurich, Switzerland.

Medulloblastomas (MB) are the most common malignant brain tumors in childhood. Alkylator-based drugs are effective agents in the treatment of patients with MB. In several tumors, including malignant glioma, elevated O(6)-methylguanine-DNA methyltransferase (MGMT) expression levels or lack of MGMT promoter methylation have been found to be associated with resistance to alkylating chemotherapeutic agents such as temozolomide (TMZ). In this study, we examined the MGMT status of MB and central nervous system primitive neuroectodermal tumor (PNET) cells and two large sets of primary MB. In seven MB/PNET cell lines investigated, MGMT promoter methylation was detected only in D425 human MB cells as assayed by the qualitative methylation-specific PCR and the more quantitative pyrosequencing assay. In D425 human MB cells, MGMT mRNA and protein expression was clearly lower when compared with the MGMT expression in the other MB/PNET cell lines. In MB/PNET cells, sensitivity towards TMZ and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) correlated with MGMT methylation and MGMT mRNA expression. Pyrosequencing in 67 primary MB samples revealed a mean percentage of MGMT methylation of 3.7-92% (mean: 13.25%, median: 10.67%). Percentage of MGMT methylation and MGMT mRNA expression as determined by quantitative RT-PCR correlated inversely (n = 46; Pearson correlation r (2) = 0.14, P = 0.01). We then analyzed MGMT mRNA expression in a second set of 47 formalin-fixed paraffin-embedded primary MB samples from clinically well-documented patients treated within the prospective randomized multicenter trial HIT'91. No association was found between MGMT mRNA expression and progression-free or overall survival. Therefore, it is not currently recommended to use MGMT mRNA expression analysis to determine who should receive alkylating agents and who should not.

UI MeSH Term Description Entries
D007124 Immunoenzyme Techniques Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens. Antibody Enzyme Technique, Unlabeled,Enzyme Immunoassay,Enzyme-Labeled Antibody Technique,Immunoassay, Enzyme,Immunoperoxidase Techniques,Peroxidase-Antiperoxidase Complex Technique,Peroxidase-Labeled Antibody Technique,Antibody Enzyme Technic, Unlabeled,Enzyme-Labeled Antibody Technic,Immunoenzyme Technics,Immunoperoxidase Technics,Peroxidase-Antiperoxidase Complex Technic,Peroxidase-Labeled Antibody Technic,Antibody Technic, Enzyme-Labeled,Antibody Technic, Peroxidase-Labeled,Antibody Technics, Enzyme-Labeled,Antibody Technics, Peroxidase-Labeled,Antibody Technique, Enzyme-Labeled,Antibody Technique, Peroxidase-Labeled,Antibody Techniques, Enzyme-Labeled,Antibody Techniques, Peroxidase-Labeled,Enzyme Immunoassays,Enzyme Labeled Antibody Technic,Enzyme Labeled Antibody Technique,Enzyme-Labeled Antibody Technics,Enzyme-Labeled Antibody Techniques,Immunoassays, Enzyme,Immunoenzyme Technic,Immunoenzyme Technique,Immunoperoxidase Technic,Immunoperoxidase Technique,Peroxidase Antiperoxidase Complex Technic,Peroxidase Antiperoxidase Complex Technique,Peroxidase Labeled Antibody Technic,Peroxidase Labeled Antibody Technique,Peroxidase-Antiperoxidase Complex Technics,Peroxidase-Antiperoxidase Complex Techniques,Peroxidase-Labeled Antibody Technics,Peroxidase-Labeled Antibody Techniques,Technic, Enzyme-Labeled Antibody,Technic, Immunoenzyme,Technic, Immunoperoxidase,Technic, Peroxidase-Antiperoxidase Complex,Technic, Peroxidase-Labeled Antibody,Technics, Enzyme-Labeled Antibody,Technics, Immunoenzyme,Technics, Immunoperoxidase,Technics, Peroxidase-Antiperoxidase Complex,Technics, Peroxidase-Labeled Antibody,Technique, Enzyme-Labeled Antibody,Technique, Immunoenzyme,Technique, Immunoperoxidase,Technique, Peroxidase-Antiperoxidase Complex,Technique, Peroxidase-Labeled Antibody,Techniques, Enzyme-Labeled Antibody,Techniques, Immunoenzyme,Techniques, Immunoperoxidase,Techniques, Peroxidase-Antiperoxidase Complex,Techniques, Peroxidase-Labeled Antibody
D008130 Lomustine An alkylating agent of value against both hematologic malignancies and solid tumors. CCNU,Belustine,Cecenu,CeeNU,NSC-79037,NSC 79037,NSC79037
D008297 Male Males
D008527 Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1) Arachnoidal Cerebellar Sarcoma, Circumscribed,Medulloblastoma, Desmoplastic,Medullomyoblastoma,Sarcoma, Cerebellar, Circumscribed Arachnoidal,Medulloblastoma, Adult,Medulloblastoma, Childhood,Melanocytic Medulloblastoma,Adult Medulloblastoma,Adult Medulloblastomas,Childhood Medulloblastoma,Childhood Medulloblastomas,Desmoplastic Medulloblastoma,Desmoplastic Medulloblastomas,Medulloblastoma, Melanocytic,Medulloblastomas,Medulloblastomas, Adult,Medulloblastomas, Childhood,Medulloblastomas, Desmoplastic,Medulloblastomas, Melanocytic,Medullomyoblastomas,Melanocytic Medulloblastomas
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002528 Cerebellar Neoplasms Primary or metastatic neoplasms of the CEREBELLUM. Tumors in this location frequently present with ATAXIA or signs of INTRACRANIAL HYPERTENSION due to obstruction of the fourth ventricle. Common primary cerebellar tumors include fibrillary ASTROCYTOMA and cerebellar HEMANGIOBLASTOMA. The cerebellum is a relatively common site for tumor metastases from the lung, breast, and other distant organs. (From Okazaki & Scheithauer, Atlas of Neuropathology, 1988, p86 and p141) Benign Cerebellar Neoplasms,Cerebellar Cancer,Malignant Cerebellar Neoplasms,Cerebellar Neoplasms, Benign,Cerebellar Neoplasms, Malignant,Cerebellar Neoplasms, Primary,Cerebellar Tumors,Neoplasms, Cerebellar,Neoplasms, Cerebellar, Benign,Neoplasms, Cerebellar, Malignant,Neoplasms, Cerebellar, Primary,Primary Neoplasms, Cerebellum,Benign Cerebellar Neoplasm,Cancer, Cerebellar,Cerebellar Cancers,Cerebellar Neoplasm,Cerebellar Neoplasm, Benign,Cerebellar Neoplasm, Malignant,Cerebellar Neoplasm, Primary,Cerebellar Tumor,Cerebellum Primary Neoplasm,Cerebellum Primary Neoplasms,Malignant Cerebellar Neoplasm,Neoplasm, Benign Cerebellar,Neoplasm, Cerebellar,Neoplasm, Cerebellum Primary,Neoplasm, Malignant Cerebellar,Primary Cerebellar Neoplasm,Primary Cerebellar Neoplasms,Primary Neoplasm, Cerebellum,Tumor, Cerebellar
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children

Related Publications

Denis Faoro, and André O von Bueren, and Tarek Shalaby, and Davide Sciuscio, and Marie-Louise Hürlimann, and Lucia Arnold, and Nicolas U Gerber, and Johannes Haybaeck, and Michel Mittelbronn, and Stefan Rutkowski, and Monika Hegi, and Michael A Grotzer
March 1992, Cancer research,
Denis Faoro, and André O von Bueren, and Tarek Shalaby, and Davide Sciuscio, and Marie-Louise Hürlimann, and Lucia Arnold, and Nicolas U Gerber, and Johannes Haybaeck, and Michel Mittelbronn, and Stefan Rutkowski, and Monika Hegi, and Michael A Grotzer
December 2017, Molecular and clinical oncology,
Denis Faoro, and André O von Bueren, and Tarek Shalaby, and Davide Sciuscio, and Marie-Louise Hürlimann, and Lucia Arnold, and Nicolas U Gerber, and Johannes Haybaeck, and Michel Mittelbronn, and Stefan Rutkowski, and Monika Hegi, and Michael A Grotzer
February 2012, Neurosurgery,
Denis Faoro, and André O von Bueren, and Tarek Shalaby, and Davide Sciuscio, and Marie-Louise Hürlimann, and Lucia Arnold, and Nicolas U Gerber, and Johannes Haybaeck, and Michel Mittelbronn, and Stefan Rutkowski, and Monika Hegi, and Michael A Grotzer
July 2003, Diabetes research and clinical practice,
Denis Faoro, and André O von Bueren, and Tarek Shalaby, and Davide Sciuscio, and Marie-Louise Hürlimann, and Lucia Arnold, and Nicolas U Gerber, and Johannes Haybaeck, and Michel Mittelbronn, and Stefan Rutkowski, and Monika Hegi, and Michael A Grotzer
July 2015, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire,
Denis Faoro, and André O von Bueren, and Tarek Shalaby, and Davide Sciuscio, and Marie-Louise Hürlimann, and Lucia Arnold, and Nicolas U Gerber, and Johannes Haybaeck, and Michel Mittelbronn, and Stefan Rutkowski, and Monika Hegi, and Michael A Grotzer
June 2005, Journal of chemotherapy (Florence, Italy),
Denis Faoro, and André O von Bueren, and Tarek Shalaby, and Davide Sciuscio, and Marie-Louise Hürlimann, and Lucia Arnold, and Nicolas U Gerber, and Johannes Haybaeck, and Michel Mittelbronn, and Stefan Rutkowski, and Monika Hegi, and Michael A Grotzer
January 1983, Postepy biochemii,
Denis Faoro, and André O von Bueren, and Tarek Shalaby, and Davide Sciuscio, and Marie-Louise Hürlimann, and Lucia Arnold, and Nicolas U Gerber, and Johannes Haybaeck, and Michel Mittelbronn, and Stefan Rutkowski, and Monika Hegi, and Michael A Grotzer
September 2013, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology,
Denis Faoro, and André O von Bueren, and Tarek Shalaby, and Davide Sciuscio, and Marie-Louise Hürlimann, and Lucia Arnold, and Nicolas U Gerber, and Johannes Haybaeck, and Michel Mittelbronn, and Stefan Rutkowski, and Monika Hegi, and Michael A Grotzer
June 2010, Lung cancer (Amsterdam, Netherlands),
Denis Faoro, and André O von Bueren, and Tarek Shalaby, and Davide Sciuscio, and Marie-Louise Hürlimann, and Lucia Arnold, and Nicolas U Gerber, and Johannes Haybaeck, and Michel Mittelbronn, and Stefan Rutkowski, and Monika Hegi, and Michael A Grotzer
January 2010, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!